Trial Profile
A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab Plus Docetaxel (TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms BOLD-1
- 31 Dec 2021 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
- 31 Dec 2021 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2021.
- 31 Dec 2021 Status changed from recruiting to active, no longer recruiting.